Subscribe
Area Development Magazine Current Issue
  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Renew

Hikma Pharmaceuticals Plans Columbus-Bedford, Ohio, Biomanufacturing Operations

06/16/2026
Pharmaceutical manufacturer Hikma Pharmaceuticals plans to expand its operations in Columbus and Bedford, Ohio. The $267 million project is expected to create 350 jobs.

The investment at the company’s existing Bedford facility will increase sterile injectable manufacturing capabilities, including aseptic vial filling, lyophilization, IV bag production, warehousing, and distribution. The expansion at the Columbus site will increase oral solid dose and nasal inhalation manufacturing operations.

“We are pleased that a significant amount of the new U.S. investments we announced last June will be spent in Ohio to further expand Hikma’s capacity to develop and manufacture medicines that will help millions of American patients,” said Hafrun Fridriksdottir, President of Hikma US and Chief R&D Officer. “Hikma is grateful to Governor DeWine, JobsOhio, and other state and local partners for their support. We are proud to continue building our Ohio workforce and our ability to make safe, affordable, high-quality medicines in Ohio for American patients.”

To support the project the Ohio Tax Credit Authority approved a 1.878 percent, 15-year Job Creation Tax Credit. “Alongside our partners at Team NEO and One Columbus, we celebrate Hikma’s growth statewide,” noted J.P. Nauseef, President and CEO of JobsOhio. “These investments in Bedford and Columbus are part of the company’s $1 billion strategic commitment to domestic pharmaceutical manufacturing, and Hikma continues to serve as an example of why the future of medicine is being built in Ohio.”

Hikma Pharmaceuticals is a manufacturer of generic, branded, and injectable medicines. The company develops, manufactures, and distributes pharmaceutical products across a range of therapeutic categories.

“Hikma Pharmaceuticals USA Inc.’s expansion in Bedford will extend well beyond the city itself – strengthening the regional economy, supporting suppliers and creating opportunities for our 14-county region,” added Matt Dolan, CEO of Team NEO. “We welcome this expansion and the positive impact it will have in strengthening an industry that improves lives.”

“Hikma’s continued investment in Columbus reflects a high level of confidence in the region’s talent, infrastructure and capacity for innovation,” said Jonas Peterson, Chief Economic Development Officer at the Columbus Partnership and President of One Columbus. “This expansion builds on that foundation and reinforces the Columbus Region as a place where companies can scale and serve critical needs nationally.”

Magazine

Past Issues
Area Development Magazine Q1 2026
Q1 2026

Receive quarterly issues of Area Development Magazine at no charge for qualified executives and consultants to industry.

Exclusive Research